SS Innovations International Inc. (NASDAQ: SSII), a developer of surgical robotic technologies, has appointed veteran medtech finance executive Sarah M. Romano as chief financial officer, effective August 3, 2026. The appointment comes as the company accelerates global commercialization of its SSi Mantra robotic surgical platform and advances preparations for U.S. Food and Drug Administration review. Romano brings more than two decades of experience in public-company finance, capital markets, and medical technology, having raised more than $100 million during her career. She previously served as CFO at Vicarious Surgical, another robotic surgery developer, where she led financial and operational initiatives to reduce cash burn and strengthen the balance sheet.
The leadership addition underscores SS Innovations' strategic focus on financial discipline and regulatory progress as it expands internationally. The company recently graduated the inaugural class of its SS International Centre for Robotics Surgery cardiac robotic surgery training program, which welcomed 33 healthcare professionals from seven countries. This initiative highlights the company's emphasis on surgeon education alongside technology deployment, a critical factor for adoption of robotic systems in complex procedures. The SSi Mantra system, designed for minimally invasive surgery, is already in use in select international markets, and the company is building a pipeline of trained surgeons to support broader commercial rollouts.
Romano's appointment arrives at a pivotal moment for SS Innovations, which is balancing the high costs of regulatory submissions and global expansion with the need to demonstrate a sustainable business model. Her experience in capital markets and operational finance is expected to help the company navigate these challenges. The company's newsroom provides updates on regulatory and business developments. The SSi Mantra system's path to FDA clearance remains a key catalyst, as U.S. approval would open the world's largest medical device market. Meanwhile, the training program's success in attracting international participants signals growing demand for robotic surgery solutions in emerging markets.
The convergence of Romano's financial expertise and the company's operational milestones positions SS Innovations to potentially accelerate its growth trajectory. Investors and industry observers will be watching for further updates on FDA interactions and commercial expansion in the coming months.
